Cost-effectiveness of outpatient COVID-19 antiviral treatment with nirmatrelvir/ritonavir versus usual care in Swedish patients with various risk factors
This study shows that NMV/r is a cost-effective or even cost-saving treatment option for many patient cohorts, including most elderly and not-recently vaccinated patients with at least some comorbidity burden.
Authors
- Martina Aldvén
- Tendai Mugwagwa (ORCID: https://orcid.org/0000-0001-7515-8548)
- Christian Gerdesköld (ORCID: https://orcid.org/0000-0002-7772-5451)
- Fredrik Nilsson (ORCID: https://orcid.org/0000-0002-1905-4047)
Institutions
- Pfizer (United States) (US)
- Pfizer (United Kingdom) (GB)
- Pfizer (Sweden) (SE)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2024-12-20
- DOI
- https://doi.org/10.1080/13696998.2024.2444836
- Citations
- 2
- Primary Topic
- Long-Term Effects of COVID-19
- Type
- article
- Field-Weighted Citation Impact
- 0.74